0 82

Cited 1 times in

A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial

Authors
 Sung Yong Oh  ;  Won Seog Kim  ;  Jin Seok Kim  ;  Yee Soo Chae  ;  Gyeong-Won Lee  ;  Hyeon Seok Eom  ;  Hun Mo Ryoo  ;  Suee Lee  ;  Seok Jin Kim  ;  Dok Hyun Yoon  ;  Jong Ho Won  ;  Junshik Hong  ;  Jinny Park  ;  Sang-Min Lee  ;  Jung Yong Hong  ;  Eunkyung Park  ;  Hyo Jung Kim  ;  Deok-Hwan Yang  ;  Hyo-Jin Kim  ;  Cheolwon Suh 
Citation
 LEUKEMIA & LYMPHOMA, Vol.57(6) : 1406-1412, 2016 
Journal Title
 LEUKEMIA & LYMPHOMA 
ISSN
 1042-8194 
Issue Date
2016
MeSH
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use* ; Combined Modality Therapy ; Drug Resistance, Neoplasm ; Female ; Humans ; Lymphoma, B-Cell, Marginal Zone/diagnosis* ; Lymphoma, B-Cell, Marginal Zone/drug therapy* ; Lymphoma, B-Cell, Marginal Zone/mortality ; Male ; Middle Aged ; Neoplasm Metastasis ; Neoplasm Staging ; Organoplatinum Compounds/administration & dosage ; Prednisone/administration & dosage ; Prognosis ; Recurrence ; Retreatment ; Treatment Outcome
Keywords
Oxaliplatin ; marginal zone lymphoma ; prednisone ; refractory ; relapse
Abstract
Overall, more than 50% of marginal zone lymphoma (MZL) patients experience a relapse within 10 years. This phase II trial was conducted to assess the efficacy and safety of oxaliplatin-prednisone (Ox-P) chemotherapy for patients with relapsed or refractory MZL. Patients received oxaliplatin 130?mg/m(2) on day 1 and prednisone 100?mg/day on days 1-5 of each cycle. A total of 38 patients were enrolled. The median age of the 34 (16 males, 18 females) evaluated patients was 53 (range?=?27-74) years. There were seven complete responses (20.6%) and 15 partial responses (44.1%) (Overall response rate?=?64.7%). No treatment-related deaths occurred. The median progression-free survival was 14.2 months (95% CI?=?2.1-26.3 months); 3-year overall survival rate was 77.7%. Thus, salvage Ox-P chemotherapy for patients with relapsed or refractory MZL at the stated dosage and schedule showed moderate clinical activity and was considerable in very few selected patients (NCT01068392).
Full Text
http://www.tandfonline.com/doi/full/10.3109/10428194.2015.1099650
DOI
10.3109/10428194.2015.1099650
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Jin Seok(김진석) ORCID logo https://orcid.org/0000-0001-8986-8436
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/152771
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse